Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors

被引:81
作者
Geiger, J [1 ]
Hönig-Liedl, P [1 ]
Schanzenbächer, P [1 ]
Walter, U [1 ]
机构
[1] Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany
关键词
ADP derivative; thienopyridine; Ca2+; G-protein; purinoceptor;
D O I
10.1016/S0014-2999(98)00305-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human platelets express adenosine 5'-diphosphate (ADP)-specific purinoceptors of the P-2X and P-2Y receptor superfamily, but their structure, diversity, and precise pharmacological profile is not well understood. Here, functional assays with intact platelets and well-characterized nucleotide derivatives were performed in order to characterize the ligand specificity of these platelet-specific purinoceptors. For the signalling pathways investigated (aggregation, rapid Ca2+-influx, desensitization of Ca2+-influx, Ca2+-mobilization, inhibition of adenylyl cyclase), significant differences in ligand specificity were demonstrated. ADP activated all purinoceptors of human platelets, while adenosine 5'-triphosphate (ATP) was a weak agonist for the P-2X receptor and an antagonist for the P-2Y receptors, The ADP-receptor pathway-antagonist ticlopidine inhibited ADP-evoked aggregation and adenylyl cyclase inhibition but did not affect platelet purinoceptors associated with Ca2+-influx and Ca2+-mobilization. These results indicate the presence of three distinct ADP-selective purinoceptors on human platelets. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:235 / 246
页数:12
相关论文
共 35 条
[1]   ADENOSINE-DIPHOSPHATE AS A MEDIATOR OF PLATELET-AGGREGATION INVIVO - AN EDITORIAL VIEW [J].
BORN, GVR .
CIRCULATION, 1985, 72 (04) :741-746
[2]  
COLE B, 1971, ANN NY ACAD SCI, V185, P477
[3]   Molecular basis for ADP-induced platelet activation I. Evidence for three distinct ADP receptors on human platelets [J].
Daniel, JL ;
Dangelmaier, C ;
Jin, JG ;
Ashby, B ;
Smith, JB ;
Kunapuli, SP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) :2024-2029
[4]  
EVANS RJ, 1995, MOL PHARMACOL, V48, P178
[5]   Towards a revised nomenclature for P1 and P2 receptors [J].
Fredholm, BB ;
Abbracchio, MP ;
Burnstock, G ;
Dubyak, GR ;
Harden, TK ;
Jacobson, KA ;
Schwabe, U ;
Williams, M .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (03) :79-82
[6]  
GAARDER A., 1961, NATURE, V192, P531, DOI 10.1038/192531a0
[7]  
Gachet C, 1997, THROMB HAEMOSTASIS, V78, P271
[8]   REGULATION OF CALCIUM MOBILIZATION AND ENTRY IN HUMAN PLATELETS BY ENDOTHELIUM-DERIVED FACTORS [J].
GEIGER, J ;
NOLTE, C ;
WALTER, U .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 267 (01) :C236-C244
[9]   ROLE OF CGMP AND CGMP-DEPENDENT PROTEIN-KINASE IN NITROVASODILATOR INHIBITION OF AGONIST-EVOKED CALCIUM ELEVATION IN HUMAN PLATELETS [J].
GEIGER, J ;
NOLTE, C ;
BUTT, E ;
SAGE, SO ;
WALTER, U .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (03) :1031-1035
[10]  
Geiger J, 1993, EXS, V66, P281